Pharmacological profile of preparation Оfor in the aspect of rational antimicrobial therapy for mixed infections
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The review presents the analysis of pharmacological properties of a medicinal product Ofor is a fixed combination of 200 mg of ofloxacin and 500 mg of ornidazole with the criterion of «necessity and sufficiency» in relation to the choice of a rational antimicrobial therapy of mixed infections. It is shown that combination of оfloxacin with ornidazole most fully encompasses a broad range of pathogens mixed urogenital infections and is characterized by high efficiency and good tolerability in the treatment of patients with infectious-inflammatory diseases of the pelvic organs in gynecology, the treatment of demodecosis and acne in dermatology, mixed infections of the abdominal cavity and biliary tract, the respiratory system. It is noted that the Ofor has high safety profile, due to the peculiarities of pharmacokinetics and pharmacodynamics of its ingredients; has a combined antimicrobial and antiprotozoal effect, practically without disturbing the quality of normality of the urogenital system and intestines; has a high compliance (is a handy combination for «voluntary compliance, the patient is prescribed the drug regimen»); is available for optimal ten-day course. It is emphasized that the ease of use (1–2 tablets a day) and affordability make the Ofor a drug of choice in the treatment of sexually transmitted infections, inflammatory and infectious diseases of the pelvis and genitourinary system.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Osobennosti techenija meningojencefalita u rebenka so smeshannoj bakterial'noj infekciej / N.V. Skripchenko, E.M. Mazaeva, M.K. Behtereva, M.V. Ivanova // Zhurn. infektologii. – 2013. – T. 5, № 1. – S. 103–107.
Sindic C.J. Clinical relevance of polymerase chain reaction (PCR) assays and antigen driven immunoblots for the diagnosis of neurological infectious diseases / C.J. Sindic, M.P. Van Antwerpen, S. Goffette // Brain Res. Bull. – 2003. – Vol. 61, № 3. – P. 299–308.
Tihomirova O.V. Ostrye kishechnye infekcii smeshannoj jetiologii: osobennosti techenija i terapii / O.V. Tihomirova // Terapija infekcionnyh zabolevanij u detej: sovremennye predstavlenija i nereshennye voprosy. Materialy konferencii NPK. – 2005. – S. 122.
Popova O.V. Kliniko-immunologicheskaja harakteristika iersinioznoj infekcii / O.V. Popova, I.V. Shepeleva, I.V. Shestakova // Infekcionnye bolezni. – 2006. – T. 4, № 3. – S. 51–55.
Ivanova V.V. Immunopatogenez infekcionnyh boleznej u detej / V.V. Ivanova // Detskie infekcii. – 2005. – T. 4, № 1. – S. 6–11.
Jurusova E.N. Kliniko-patogeneticheskaja harakteristika sochetannyh iersinioznyh infekcij u detej: Avtoref. diss. … kand. med. nauk / E.N. Jurusova. – Vladivostok, 2009. – 154 s.
Letjaeva O.I. Optimizacija podhodov k terapii urogenital'nyh mikstinfekcij u zhenshhin reproduktivnogo vozrasta: Tezisy XXXII nauchno-prakticheskoj konferencii «Rahmanovskie chtenija» // Dermatologija v Rossii. – 2015. – T.4, vyp. S1. – S. 35.
Makoveckaja M. Racional'naja terapija urogenital'nyh mikst-infekcij: v fokuse kombinacija ciprofloksacin/ornidazol / M. Makoveckaja // Zdorov’ja Ukrai'ni HHI storichchja. – 2013. – № 19. – S. 57.
Vremja fiksirovannyh kombinacij lekarstvennyh preparatov: ofloksacin + ornidazol. – Medicus Amicus. – 2006. [Jelektronnyj resurs]: Rezhim dostupa – www.medicusamicus.
Tihomirov A.L. Sovremennyj algoritm terapii vospalitel'nyh zabolevanij polovoj sfery / A.L. Tihomirov, V.N. Judaev, D.M. Lubnin // Medicinskaja panorama. – 2003. – № 9. – S. 40–44.
Introduction to Drug Utilization Research / WHO International Working Group for Drug Statistics M 1. ethodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. – WHO. – 2003. – 50 p.
Evropejskie standarty diagnostiki i lechenija zabolevanij, peredavaemyh polovym putem. – K.: Med. literatura, 2003. – 264 s.
Pro zatverdzhennja klinichnih protokoliv nadannja medichnoi' dopomogi hvorim na dermatovenerologichni zahvorjuvannja. Nakaz MOZ Ukrai'ni № 312 vid 08.05.2009 r. [Jelektronnyj resurs]: Rezhim dostupa – www.document.ua
Popov S.V. Kombinirovannaja antimikrobnaja terapija urogenital'nyh infekcij u muzhchin/ S.V. Popov // Jeksperimental'naja i klinicheskaja urologija. – 2013. – № 2. – S. 116–120.
Profilaktika posleabortnyh infekcionno-vospalitel'nyh oslozhnenij/ M.V. Majorov, S.I. Zhuchenko, E.A. Zhuperkova, O.L. Chernjak // Medicinskie aspekty zdorov'ja zhenshhiny. – 2015. – № 4 (90). – S. 37–42.
Kuhar' O.P. Sovremennye antimikrobnye preparaty / O.P. Kuhar', D.V. Mamchur, V.I. Mamchur. – Dnepropetrovsk, 2006. – 74 s.
Jakovlev V.P. Mesto ofloksacina v ambulatornoj praktike: opyt 15letnego primenenija/ V.P. Jakovlev // Infekcii i antimikrobnaja terapija. – 2000. – T. 2, № 5. – S. 154–156.
Antibiotiki i protivoinfekcionnyj immunitet /Pod red. N.D. Jushhuka, I.P. Balmasovoj, V.N. Careva. – M.: Prakticheskaja medicina, 2012. – S. 208–221.
Dalhoff A. Immunomodulatory effects of quinolones/ A. Dalhoff, I. Shalit // Lancet Infect Dis. – 2003. – Vol. 3, № 7. – P. 359–371.
Padejskaja E.N. Ofloksacin (Tarivid). Antibakterial'nyj preparat iz gruppy ftorhinolonov/ E.N. Padejskaja, V.P. Jakovlev. – M., 1996. – 116 s.
Kogan B.G. Nitroimidazoly vchera i segodnja: 50 let v bor'be s trihomoniazom/ B.G. Kogan, Ju.G. Bondarenko// Reproduktivnoe zdorov'e zhenshhiny. – 2007. – № 5 (34). – S. 13–19.
Padejskaja E.N. 5-Nitroimidazoly – antimikrobnye preparaty dlja lechenija bakterial'nyh i protozojnyh infekcij/ E.N. Padejskaja // Consilium medicum. – 2004. – T. 6, № 1. – S. 32–40.
Bratzler D.W. Antimicrobial prophylaxis for surgery an advisory statement from national surgical infection prevention project/ D.W. Bratzler, P.M. Houck // Clin. Infect. Dis. – 2004. – Vol. 38. – P. 1706–1715.
Hrjanin A.A. Problema vybora v lechenii trihomonadnoj infekcii: metronidazol ili ornidazol? / A.A. Hrjanin // Klinicheskaja dermatologija i venerologija. – 2006. – № 4. – S. 51–53.
Inceboz T. Comparative in vitro cytotoxic effects of ornidazole, metronidazole and ciprofloxacin against Trichomonas vaginalis trophozoites/ T. Inceboz, U. Inceboz, S. Ozturk // J. Chemother. – 2004. – Vol. 16, № 5. – P. 459–462.
Gorpinchenko I.I. Issledovanie klinicheskoj jeffektivnosti i bezopasnosti preparata Ofor v lechenii mikst-infekcii mochepolovoj sistemy u muzhchin/ I.I. Gorpinchenko, Ju.N. Gurzhenko, N.S. Strizhak // Zdorov'e muzhchiny. – 2009. – № 3 (30). – S. 32–38.
Potapov V.A. Bezopasnost' i jeffektivnost' kombinirovannogo preparata OFOR (ofloksacin+ornidazol) v terapii bakterial'nogo vaginoza/ V.A. Potapov, V.I. Chujko, T.R. Strel'cova. – 2010. [Jelektronnyj resurs]: Rezhim dostupa – www.organosyn.com.ua.
Vdovichenko Ju.P. Bakterial'nyj vaginoz – sovremennye podhody k lecheniju i profilaktike recidivov/ Ju.P. Vdovichenko, M.V. Himenko, S.I. Soboleva. – 2009. [Jelektronnyj resurs]: Rezhim dostupa – www.organosyn.com.ua.
Efektivnist' vikoristannja kombinovanogo preparatu OFOR u kompleksnij terapii' gostrogo sal'pingooforitu/ A.Ja. Senchuk, I.O. Doskoch, L.M. Dmitrichenko, S.V. Ivanenko// Zdorov'e zhenshhiny. – 2012. – № 9. – S. 123–128.
Shupen'ko E.N. Opyt primenenija kombinirovannogo preparata OFOR v kompleksnom lechenii demodekoza i ugrevoj bolezni/ E.N. Shupen'ko, E.N. Shupen'ko N.M. // Ukrai'ns'kij zhurnal dermatologii', venerologii', kosmetologii'. – 2013. – № 2. – S. 41–46.
Ofor. Instrukcija dlja medicinskogo primenenija preparata. [Jelektronnyj resurs]: Rezhim dostupa – www.medguru.ua.
Prakticheskoe rukovodstvo po antiinfekcionnoj himioterapii / Pod red. Strachunskij L.S., Belousov Ju.B., Kozlov S.N. – M.: Borges, 2002. – 384 s.
